Published in Medical Letter on the CDC and FDA, January 20th, 2002
The U.S. Food and Drug Administration, which spent the week of December 20, 2001, inspecting BioPort Corp.'s labs, said that the company had satisfactorily addressed most of the procedures it wanted to see fixed before allowing the company to ship the vaccine.
"We are very pleased with the results of this inspection,'' BioPort spokeswoman Kim Brennen Root said. The company already has corrected four of the seven problems cited by the FDA, she said.
BioPort has been under pressure to win...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA